Last Updated: May 3, 2026

Ibsa Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Ibsa
International Patents:30
US Patents:7
Tradenames:6
Ingredients:4
NDAs:6
Patent Litigation for Ibsa: See patent lawsuits for Ibsa

Drugs and US Patents for Ibsa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ibsa TIROSINT-SOL levothyroxine sodium SOLUTION;ORAL 206977-011 Dec 15, 2016 RX Yes No 11,241,382 ⤷  Start Trial ⤷  Start Trial
Ibsa TIROSINT-SOL levothyroxine sodium SOLUTION;ORAL 206977-002 Dec 15, 2016 RX Yes No 11,096,913 ⤷  Start Trial Y ⤷  Start Trial
Ibsa TIROSINT-SOL levothyroxine sodium SOLUTION;ORAL 206977-005 Dec 15, 2016 RX Yes No 11,241,382 ⤷  Start Trial ⤷  Start Trial
Ibsa TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-014 Jun 22, 2022 RX Yes No 12,564,565 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ibsa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ibsa TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-008 Oct 2, 2009 7,691,411 ⤷  Start Trial
Ibsa TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-003 Oct 13, 2006 7,691,411 ⤷  Start Trial
Ibsa TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-006 Oct 13, 2006 7,691,411 ⤷  Start Trial
Ibsa TIROSINT levothyroxine sodium CAPSULE;ORAL 021924-002 Oct 13, 2006 7,691,411 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for IBSA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Patch 1.3% ➤ Subscribe 2015-06-26

Supplementary Protection Certificates for Ibsa Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0463756 C990005 Netherlands ⤷  Start Trial PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756 99C0007 Belgium ⤷  Start Trial PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756 5/1999 Austria ⤷  Start Trial PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756 SPC/GB99/004 United Kingdom ⤷  Start Trial PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.